Indication
Gastric Type Adenocarcinoma with STK11 Mutation
1 clinical trial
2 products
Product
WX390Clinical trial
A Phase II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 MutationsStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Toripalimab